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Real-Time PCR Assay for Detection and Differentiation of Shiga
Toxin-Producing Escherichia coli from Clinical Samples
Xuan Qin,a,b Eileen J. Klein,c Emmanouil Galanakis,a Anita A. Thomas,c Jennifer R. Stapp,a Shannon Rich,a Anne Marie Buccat,a
Phillip I. Tarrd
Microbiology Laboratory, Seattle Children’s Hospital, Seattle, Washington, USAa; Department of Laboratory Medicineb and Department of Pediatrics,c University of
Washington School of Medicine, Seattle, Washington, USA; Departments of Pediatrics and Molecular Microbiology, Washington University School of Medicine, St. Louis,
Missouri, USAd
Timely accurate diagnosis of Shiga toxin-producing Escherichia coli (STEC) infections is important. We evaluated a laboratory-
developed real-time PCR (LD-PCR) assay targeting stx1, stx2, and rfbEO157 with 2,386 qualifying stool samples submitted to the
microbiology laboratory of a tertiary care pediatric center between July 2011 and December 2013. Broth cultures of PCR-positive
samples were tested for Shiga toxins by enzyme immunoassay (EIA) (ImmunoCard STAT! enterohemorrhagic E. coli [EHEC];
Meridian Bioscience) and cultured in attempts to recover both O157 and non-O157 STEC. E. coli O157 and non-O157 STEC
were detected in 35 and 18 cases, respectively. Hemolytic uremic syndrome (HUS) occurred in 12 patients (10 infected with STEC
O157, one infected with STEC O125ac, and one with PCR evidence of STEC but no resulting isolate). Among the 59 PCR-positive
STEC specimens from 53 patients, only 29 (54.7%) of the associated specimens were toxin positive by EIA. LD-PCR differenti-
ated STEC O157 from non-O157 using rfbEO157, and LD-PCR results prompted successful recovery of E. coli O157 (n 25) and
non-O157 STEC (n 8) isolates, although the primary cultures and toxin assays were frequently negative. A rapid “mega”-mul-
tiplex PCR (FilmArray gastrointestinal panel; BioFire Diagnostics) was used retrospectively, and results correlated with LD-PCR
findings in 25 (89%) of the 28 sorbitol-MacConkey agar culture-negative STEC cases. These findings demonstrate that PCR is
more sensitive than EIA and/or culture and distinguishes between O157 and non-O157 STEC in clinical samples and that E. coli
O157:H7 remains the predominant cause of HUS in our institution. PCR is highly recommended for rapid diagnosis of pediatric
STEC infections.
Shiga toxin-producing Escherichia coli (STEC) and especially E.coli O157:H7 are worldwide pathogens. Their importance is
derived from the severity of the illnesses they cause, including
diarrhea, bloody diarrhea, and hemolytic uremic syndrome
(HUS), and their epidemic potential. Good clinical management
depends on rapid accurate microbiological diagnosis (1, 2), be-
cause etiological information leads to avoidance of antibiotics (1,
3) and prompts hospital admissions and contact precautions to
minimize secondary spread within the community (4) and
nephroprotective intravenous volume expansion to avert hemo-
concentration, which has a poor prognosis if HUS develops (2, 5).
Diagnostic strategies to detect STEC vary according to sero-
type. STEC O157:H7 has the strongest and most enduring associ-
ation with HUS (6, 7) and is best isolated on sorbitol-MacConkey
(SMAC) agar, which exploits the unusual non-sorbitol-ferment-
ing phenotype of this serotype. Most other STEC serotypes fer-
ment sorbitol (as do most commensal E. coli strains) and have few
unifying phenotypes other than toxin production; therefore, toxin
assays of overnight broth cultures are used to detect these agents in
stools. The Centers for Disease Control and Prevention (CDC)
recommends routine laboratory testing for Shiga toxin-producing
bacteria (8), but toxin assays are inexplicably suboptimal for the
detection of toxin-producing E. coli O157:H7 (9).
Molecular testing for STEC is not routinely used in clinical
settings, despite supportive data (10–12). PCR assays have rou-
tinely used stx1 and stx2 as targets but cannot, by themselves, dis-
tinguish O157 from non-O157 STEC, although stx1-positive sig-
nals are unlikely to originate from O157 STEC unless stx2 is also
detected (13, 14).
Here, we compared a laboratory-developed real-time PCR
(LD-PCR) assay targeting stx1, stx2, and rfbEO157, a commercial
lateral flow enzyme immunoassay (EIA) (Meridian Bioscience,
Inc., Cincinnati, OH), and sorbitol-MacConkey agar culture. The
rfbEO157 gene encodes perosamine synthase, the first O157 STEC
rfb locus to be cloned and sequenced (15), and has been identified
in food and human samples (16, 17). To our knowledge, this is the
first study to apply PCR for rfbEO157 to distinguish O157 from
non-O157 STEC in a clinical microbiology laboratory. As part of
this investigation, the specimens and their associated MacConkey
(MAC) broth cultures that were positive by LD-PCR were ar-
chived for an additional molecular assay, the rapid “mega”-mul-
tiplex PCR (RM-PCR) with the FilmArray gastrointestinal panel
(BioFire Diagnostics, Salt Lake City, UT).
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MATERIALS AND METHODS
Setting. All qualifying stool samples from patients less than 21 years of age
that were submitted to the microbiology laboratory at Seattle Children’s
Hospital (Seattle, WA) between July 2011 and December 2013 for detec-
tion of bacterial pathogens were evaluated. From a total of 2,849 speci-
mens, 2,386 were included in this analysis after the elimination of repeat
specimens (i.e., specimens obtained from the same patient within a
2-week period and testing negative by PCR) (n 156) and specimens not
qualified for Shiga toxin testing (n 307), such as specimens submitted
on swabs (n  4) and cultures with no Gram-negative bacterial growth
(n 68) or no bacterial growth at all (n 235). This retrospective study
was approved by the institutional review board of Seattle Children’s Hos-
pital. Clinical records for all 54 patients with laboratory detection of stx1,
stx2, and/or rfbEO157 were reviewed. HUS was defined as hemolytic ane-
mia (hematocrit level of 30% with smear evidence of intravascular
erythrocyte destruction), thrombocytopenia (platelet count of150,000
platelets/mm3), and azotemia (serum creatinine level above the upper
limit of the normal range for age) (18).
Conventional culture. All stool samples were plated on sheep blood,
Hektoen enteric, MacConkey (MAC), Salmonella-Shigella, sorbitol-Mac-
Conkey (SMAC), and Campylobacter- and Yersinia-selective agars, ac-
cording to our laboratory protocols (19, 20). The specimens were also
inoculated into Selenite F broth for enrichment of Salmonella spp. and
MAC broth for enrichment of all Enterobacteriaceae, including E. coli.
Cultures were evaluated for Salmonella spp., Shigella spp., Campylobacter
spp., E. coli O157, Yersinia spp., Aeromonas spp., Plesiomonas spp., and
Vibrio spp. (19, 20). For growth-based detection of O157 STEC, SMAC
agar plates were incubated for 18 to 22 h at 35°C and then examined for
non-sorbitol-fermenting colonies. Colorless colonies were tested for the
presence of the O157 lipopolysaccharide antigen by latex agglutination
(Oxoid Ltd., Basingstoke, United Kingdom) (19, 20). Colonies positive
for the O157 antigen were subjected to biochemical testing using the Vitek
2 Compact system (bioMérieux, Marcy l’Etoile, France) and LD-PCR.
Enzyme immunoassay. Following MAC broth enrichment and real-
time PCR, 50 l of any PCR-positive MAC broth was tested using the
lateral flow EIA ImmunoCard STAT! enterohemorrhagic E. coli (EHEC)
assay (Meridian Bioscience, Inc.), according to the manufacturer’s in-
structions. The EIA-positive samples were defined as samples with visible
bands for Stx1 and/or Stx2.
LD-PCR for STEC. After incubation for 18 to 22 h at 35°C, bacterial
growth in MAC broth was determined visually by turbidity and then the
samples were submitted for PCR. For each sample, bacterial DNA was
obtained using EasyMAG automated extraction (bioMérieux, Marcy
l’Etoile, France). For specimens positive for any PCR locus, repeat testing
using both the bacterial growth material from the same MAC broth and
the heavy growth area from the MAC plates was performed to confirm the
PCR results. According to the EasyMAG manufacturer’s instructions, 200
l of incubated MAC broth was extracted, and DNA was eluted into 100
l of elution buffer. O157 positive-control broth (positive for all targets)
at high and low concentrations (500 and 50 copies/reaction, respectively)
and a negative-control broth extraction sample were extracted in each
batch run along with MAC enrichment broth containing patient samples.
The PCR primers and probes used for the multitarget detection of STEC
are listed in Table S1 in the supplemental material. As internal controls,
ECgyrA primers were designed to target conserved E. coli gyrA gene se-
quences flanking the quinolone resistance-determining region (21). The
specificity of each primer was screened by BLAST analysis and validated
using 30 clinical specimens with diagnoses, confirmed by culture, of Shiga
toxin-producing E. coli or non-E. coli pathogens, as described above. Real-
time PCR was performed with a final reaction volume of 40l containing
iQ SYBR Green Supermix (2), primers at a final concentration of 500
nM, uracil DNA glycosylase (Roche, Indianapolis, IN), and 4 l of ex-
tracted DNA.
The real-time PCR assay was performed using a Bio-Rad MyiQ iCycler
system (Bio-Rad, Hercules, CA). Simultaneous multiwell SYBR reactions
were performed to detect stx1, stx2, rfbEO157, and ECgyrA using the follow-
ing conditions: denaturation at 95°C for 1 min; amplification in 40 cycles
of 94°C for 25 s, 56°C for 25 s, and 72°C for 25 s; and final extension at
72°C for 5 min. Melting curve analysis was performed with temperatures
from 56°C to 95°C in 0.5°C increments, at a rate of 10 s/step. Positive
reactions were determined as PCR products showing specific melting
temperatures within 35 cycles. This test was validated and used in parallel
with EIA and culture for 3.5 months for all clinical samples; it demon-
strated sensitivity superior to that of EIA and culture combined prior to
this study.
RM-PCR for gastrointestinal pathogens. For MAC broths positive
for STEC, 200 l thawed broth archives were used for RM-PCR without
the addition of Cary-Blair transport medium. Also, after thawing, freezer-
archived direct stool specimens were diluted approximately 1 part speci-
men to 3 parts Protocol Cary-Blair transport medium (Thermo Scientific,
Middletown, VA), according to the manufacturer’s recommendations
(BioFire). The RM-PCR is characterized by a two-step process consisting
of a primary single multiplex PCR followed by an array of organism-
specific monoplex second-stage PCRs; it has high analytical sensitivity and
specificity, as well as rapid turnaround time (22), and it is currently ap-
proved to detect 11 bacterial, 5 viral, and 4 protozoal confirmed or
candidate pathogens, including Campylobacter, Clostridium difficile, Sal-
monella, Vibrio spp., Vibrio cholerae, Yersinia enterocolitica, enteroaggre-
gative E. coli (EAEC), enteropathogenic E. coli (EPEC), enterotoxigenic E.
coli (ETEC), STEC, Shigella/enteroinvasive E. coli (EIEC), adenovirus
F40/41, astrovirus, norovirus GI/GII, rotavirus A, sapovirus, Cryptospo-
ridium, Cyclospora cayetanensis, Entamoeba histolytica, and Giardia
lamblia.
STEC broth subculture. All MAC broths positive by real-time PCR
were subcultured onto SMAC, MAC, and Spectra urinary tract infection
(UTI) (Remel) agar plates. Suspected non-sorbitol-fermenting colonies
were worked up as described above. In cases of specimens associated with
MAC broth cultures that were reproducibly positive only for either or
both stx1 and stx2, starting from 5 or 6 colonies (and up to 30 suspected E.
coli colonies, if necessary), colonies from primary and subculture plates of
SMAC, MAC, and Spectra UTI agars were tested for the same set of targets
by LD-PCR, to identify and to isolate non-O157 STEC. Each colony was
added to water (0.5 McFarland units) and heated at 95°C for 10 min. Four
microliters of the bacterial lysate was added to each PCR. All PCR-con-
firmed STEC isolates were sent to the Washington State Public Health
Laboratory, which reported their serotypes.
Statistical analyses. The chi-square test, Fisher’s exact test, and the
McNemar test were used to evaluate categorical variables, as appropriate.
Continuous variables were analyzed nonparametrically using the Mann-
Whitney U test. Two-tailed P values of0.05 were considered statistically
significant. Statistical analyses were performed using Stata version 12.0
(StataCorp, College Station, TX), while MedCalc version 12.0 (MedCalc
Software, Mariakerke, Belgium) was used for the McNemar test.
RESULTS
STEC diagnosis and patients. Of the 2,386 qualifying samples, 53
(2.2%) contained STEC pathogens by LD-PCR. The 53 patient
specimens positive for STEC were further separated into 35 cases
positive for O157 and 18 cases positive for non-O157 STEC, as
differentiated by the specific rfbEO157 locus (Fig. 1). For four of the
35 patients with initial samples positive for STEC O157 by PCR,
repeat samples obtained 2 to 7 days later resulted in various levels
of loss of detection by either or both EIA and culture but no
change in PCR detection (data not shown). For the two patients
without diarrhea, non-O157 STEC was identified in the context of
cultures requested to investigate failure to thrive and chronic ab-
dominal pain (cases 6 and 7, respectively) (Table 1). HUS oc-
curred in 12 STEC-infected patients (22.6%; 7 male and 5 female
patients), 10 of whom were definitely infected with O157 (7 of
Molecular Diagnosis of Shiga Toxin-Producing E. coli
July 2015 Volume 53 Number 7 jcm.asm.org 2149Journal of Clinical Microbiology
 o
n
 July 15, 2015 by W
ashington University in St. Louis
http://jcm.asm.org/
D
ow
nloaded from
 
whom required dialysis) and one with STEC O125ac (case 13, not
requiring dialysis) (Table 1 and Fig. 1). These etiologies were es-
tablished before HUS developed. Two more of the 10 patients with
HUS with STEC O157 infections (both culture positive) later re-
quired dialysis but did not meet the HUS criteria at the time of
diagnosis. The stool specimen from the last patient with HUS
(case 2, not requiring dialysis and with no culture isolation of
STEC) (Table 1) was negative for rfbE but positive for both stx1
and stx2. Patients infected with O157 (22/35 patients [62.9%])
were more frequently hospitalized than were those infected with
non-O157 STEC (5/18 patients [27.8%]) (odds ratio [OR], 4.4
[95% confidence interval [CI], 1.3 to 15.2]; P  0.021), with
greater frequency of blood present in their stools (P  0.045)
(Table 2). One culture-positive STEC O157 infection in a 2-year-
old patient was accompanied by radiological evidence of intussus-
ception.
Detection of STEC by LD-PCR and retrospective correlation
with RM-PCR. Of the 53 specimens positive for STEC by LD-
PCR, 28 (10 and 18 specimens positive for O157 and non-O157
STEC, respectively) were retrospectively evaluated by RM-PCR
because of their lack of STEC isolation in routine SMAC agar
cultures (Table 1 and Fig. 1). With the exception of three archived
MAC broth-enriched specimens, RM-PCR produced the same stx
genotype as generated by LD-PCR for 25 specimens, including 9 of
the 10 culture-negative specimens (cases 20 to 28) (Table 1) pos-
itive for STEC O157 (Fig. 1). Case 23 (Table 1), which was uncon-
firmed by RM-PCR for STEC O157, involved a patient who was
admitted with abdominal pain and bloody diarrhea. If positive
samples detected by LD-PCR were considered true-positive sam-
ples, then RM-PCR achieved 89% sensitivity (positive for 25/28
samples) using the archived samples retrospectively. The differ-
ence between the 2 methods was 10.7% (95% CI, 4.5% to
10.7%) and was not statistically significant (McNemar test, P 
0.25).
There were seven direct fecal (frozen) samples available for
RM-PCR (cases 3, 8, 13, 22, 23, 26, and 28) (Table 1). The RM-
PCR results for these direct samples were identical to those for the
corresponding frozen MAC broth samples, with RM-PCR again
missing the STEC findings in the same two samples (cases 3 and 23
by LD-PCR) (Table 1). One additional sample (case 29, which was
excluded from the 53 total STEC findings) was positive for
rfbEO157 only by LD-PCR, but the isolate was a sorbitol-ferment-
ing E. coli O157 strain that lacked stx1 and stx2, and the patient did
not have diarrhea.
Among the 35 specimens characterized for the presence of E.
coli O157 based on detection of rfbEO157, stx1 and stx2 were code-
tected in 16 specimens (stx1/stx2) (Table 1), and stx2 alone (i.e.,
in the absence of stx1) was detected in 19. These stx genotypes were
confirmed in all 25 corresponding STEC O157 isolates (data not
shown). In specimens from cases 27 and 28, the detection of all 3
targets, including rfbEO157, was diagnostic for STEC O157 by LD-
PCR and was confirmed by RM-PCR, although findings were con-
founded by the presence of an O186 STEC strain (case 27, which
contained stx1 but not stx2) or an O111 STEC strain (case 28,
which was positive for both stx1 and stx2) (Table 1). These two
specimens were from 16- and 17-year-old patients, respectively,
who had just returned from Mexico with vomiting and diarrhea,
and the patient infected with STEC O111 had bloody diarrhea.
Among the 18 specimens positive for either or both stx deter-
minants but negative for rfbEO157 by LD-PCR, 16 (88.9%) were
determined by RM-PCR to contain non-O157 (Table 1 and Fig.
1). The two RM-PCR nonconfirmatory STEC cases included case
3, which was positive for both stx1 and stx2 targets, and case 10,
which was positive for stx2 only; the former patient had bloody
diarrhea and the latter was coinfected with Campylobacter jejuni.
Of the 18 patients infected with non-O157 STEC, positive LD-
PCR results for a profile of stx1
/stx2
 were found for 7 speci-
mens, stx1
/stx2
 for 9 specimens, and stx1
/stx2 for 2 speci-
mens (Table 1).
Enzyme immunoassay. The lateral flow EIA (using overnight
MAC broth-enriched specimens) provided evidence of STEC in
specimens from 29 patients (54.7%) (Fig. 1) but failed to detect 11
(31.4%) of the 35 STEC O157 cases and 13 (72.2%) of the 18
non-O157 STEC cases. Specifically, EIA results were positive for
only 2 (20%) of the 10 culture-negative specimens that were pos-
itive for O157 STEC by LD-PCR and 5 (28%) of the 18 specimens
that were positive for non-O157 STEC (Fig. 1).
Culture. Corresponding STEC organisms were isolated from
33 (62.3%) of the 53 patients (excluding cases 27 and 28), and
many would not have been further tested without PCR screening
information, i.e., if the EIA for toxin had been used for follow-up
culture evaluations. All corresponding STEC isolates recovered by
culture were also confirmed by LD-PCR and produced consistent
stx and rfbE results. The search for E. coli O157, in particular, was
successful for only 25 (71.4%) of the 35 specimens that were PCR
positive for rfbEO157, although five were toxin EIA and SMAC agar
negative. The LD-PCR results prompted us to subculture the
MAC broths on Spectra UTI agar (data not shown). Of the 18
patients whose stools contained non-O157 STEC, isolation would
not have been routinely attempted.
Culture had a sensitivity for detection of O157 STEC of 0.71
FIG 1 Characteristic findings associated with the 53 laboratory-diagnosed
STEC cases. †, case 20 in Table 1; ‡, cases 2 and 13; *, cases 27 and 28, from
which STEC 0186 and STEC O111, respectively, were isolated, were included
because the two associated specimens were positive for all three targets, includ-
ing rfbEO157.
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(95% CI, 0.5 to 0.9) (Fig. 1). Isolation of non-O157 STEC was
successful for only 8 of the 18 specimens, with a sensitivity of 0.44
(95% CI, 0.2 to 0.7), yielding STEC O26 (n  3), O121 (n  2),
and O6:H34, O125ac, and O145 (n  1 each). All O157 STEC
strains were PCR rfbEO157 positive, and all non-O157 STEC strains
were PCR rfbEO157 negative.
Coisolation of other enteric bacterial pathogens. Bacterial
enteric pathogens, including Salmonella spp. (n 57), STEC (n
53), Campylobacter spp. (n 43), Aeromonas spp. (n 37), Yer-
sinia enterocolitica (n 10), Shigella spp. (n 9), and Plesiomonas
shigelloides (n 1), were documented in 210 (8.8%) of the 2,386
patient specimens. Stool specimens from nine of the 53 STEC-
positive patients yielded additional bacterial pathogens, including
mixed STEC serotypes (n  2 cases), Aeromonas spp. (n  2
cases), C. jejuni (n 3 case), and Salmonella (n 2 cases).
DISCUSSION
Multitarget PCR sensitively detects pediatric STEC infections with
a resolution that discriminates O157 from non-O157 STEC. Ex-
cept for missing 3 cases (cases 3, 10, and 23) (Table 1) by RM-PCR,
the detection of stx1 and/or stx2, as well as rfbEO157, was in agree-
ment for LD-PCR and RM-PCR, including detection of O157
STEC (n 9) and non-O157 STEC (n 16). Detection of STEC
would not have been made for 24 patients (45%), including 3 with
severe infections and HUS, had lateral flow EIA been used alone
(Fig. 1). LD-PCR was superior to EIA and culture for samples with
low densities of STEC, in accordance with previous reports (23).
This increased sensitivity is a clear advantage, as bacterial loads
decrease rapidly during infection, particularly if cultures are not
performed early in the illness (7, 14). Low EIA sensitivity was also
TABLE 1 List of 29 cases associated with specimens that were SMAC culture negative and/or EIA negative for STEC, specimens that were positive
for stx but negative for rfbEO157, or vice versa
Case
no. Inpatient Illness characteristics
Serotype (PCR stx) of STEC
isolate Coisolate
Findings for STEC in MAC brotha Finding for
STEC in
direct stool
samples by
FilmArrayb
EIA for
Stx1 or
Stx2
PCR for
stx1 or stx2
PCR for
rfbEO157
FilmArray
gastrointestinal
panel
1 No Diarrhea No STEC isolated Stx1 stx1
 Negative STEC ND
2 Yes Bloody diarrhea, HUS,
no dialysis
No STEC isolated Negative stx1
/stx2
 Negative STEC ND
3 No Bloody diarrhea No STEC isolated Negative stx1
/stx2
 Negative Negative Negative
4 No Diarrhea No STEC isolated C. jejuni Negative stx1
 Negative STEC ND
5 No Diarrhea No STEC isolated Negative stx2
 Negative STEC ND
6 No No diarrhea (failure to
thrive)
No STEC isolated Negative stx2
 Negative STEC ND
7 No No diarrhea (chronic
abdominal pain)
No STEC isolated Negative stx2
 Negative STEC ND
8 No Bloody diarrhea No STEC isolated C. jejuni Negative stx2
 Negative STEC, C. jejuni STEC
9 Yes Diarrhea No STEC isolated Negative stx1
 Negative STEC ND
10 No No diarrhea No STEC isolated C. jejuni Negative stx2
 Negative C. jejuni (no
STEC)
ND
11 No Bloody diarrhea STEC O121 (stx2
) Stx2 stx2
 Negative STEC ND
12 Yes Diarrhea STEC O121 (stx2
) Negative stx2
 Negative STEC ND
13 Yes No diarrhea, HUS, no
dialysis
STEC O125ac (stx2
) Stx2 stx2
 Negative STEC STEC
14 No Bloody diarrhea STEC O145 (stx1
) Negative stx1
 Negative STEC ND
15 No Bloody diarrhea STEC O26 (stx1
) Stx1 stx1
 Negative STEC ND
16 No Bloody diarrhea STEC O26 (stx1
) Stx1 stx1
 Negative STEC ND
17 Yes Bloody diarrhea STEC O26 (stx1
) Salmonella sp. Negative stx1
 Negative STEC,
Salmonella
sp.
ND
18 No Diarrhea STEC O6:H34 (stx2
) Negative stx2
 Negative STEC ND
19 No Bloody diarrhea No STEC O157 isolated Stx2 stx2
 Positive STEC O157 ND
20 Yes Diarrhea, HUS,
required dialysis
No STEC O157 isolated Negative stx2
 Positive STEC O157 ND
21 No Bloody diarrhea No STEC O157 isolated Negative stx1
/stx2
 Positive STEC O157 ND
22 Yes Bloody diarrhea No STEC O157 isolated Negative stx2
 Positive STEC O157 STEC O157
23 Yes Bloody diarrhea No STEC O157 isolated Negative stx1
/stx2
 Positive Negative Negative
24 No Bloody diarrhea No STEC O157 isolated Negative stx1
/stx2
 Positive STEC O157 ND
25 No Diarrhea No STEC O157 isolated Negative stx1
/stx2
 Positive STEC O157 ND
26 Yes Bloody diarrhea No STEC O157 isolated Negative stx2
 Positive STEC O157 STEC O157
27 No No diarrhea No STEC O157 isolated, STEC
O186 (stx1
/stx2
)
Stx1 stx1
/stx2
 Positive STEC O157 ND
28 No Bloody diarrhea No STEC O157 isolated, STEC
O111 (stx1
/stx2
)
Negative stx1
/stx2
 Positive STEC O157 STEC O157
29 Yes No diarrhea E. coli O157 isolated
(stx1
/stx2
)
Negative stx1
/stx2
 Positive Negative ND
a For clarity, stx1/stx2 is used for specimens that were positive or negative for both; otherwise, either stx1 or stx2 is indicated.
b ND, not done.
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reported in other studies when PCR was used as the gold standard
(10), as well as in comparison to culture (9).
The isolation of either STEC O186 or STEC O111 (both iso-
lates negative for rfbEO157) from two specimens that were repro-
ducibly positive for all three targets, including rfbEO157 (Table 1),
indicates possible mixed STEC infections. Indeed, an inexplicably
large proportion of patients infected with non-O157 STEC are
also infected with O157 STEC (24, 25).
Based on this study, the rate of clinical HUS following a posi-
tive test for STEC of 22.6% (12/53 cases) is similar to reported
rates at academic pediatric institutions (26, 27). However, the
proportion of STEC O157 specimens with the stx/stx2 geno-
type, i.e., 54% during this study period, differs from findings re-
ported for our area (28). STEC O125ac, which was identified in
case 13, has been implicated as a human pathogen (29) in the
Netherlands. In some situations (cases 2 and 13), we cannot com-
pletely exclude the possibility of an E. coli O157 infection although
rfbE results were negative. Specifically, it is possible that rfbE was
present below the level of detection, especially in light of the pres-
ence of that target as a single locus per cell, compared to stx1 and
stx2, which are encoded on inducible bacteriophages. Similar to
previous findings, patients infected with O157 STEC were more
likely to have blood in their stools (P  0.045) (Table 2) and to
require hospitalization than were those infected with non-O157
STEC (P 0.021) (Table 2) (26, 30).
The scope of the clinical impact of our PCR assay is yet to be
appreciated. All but two of the STEC patients were acutely symp-
tomatic (Table 1), and we question the value of seeking these
pathogens (or any other enteric bacterial pathogens) in individu-
als without acute diarrhea. However, it is interesting to note that
Denno et al. failed to find STEC in any of 452 community control
children without diarrhea (19), but Bokete et al. did find a non-
O157 STEC strain in the stool of a child with chronic diarrhea
(31). With the advent of molecular technology, STEC will be de-
tected in situations other than acute gastroenteritis (11, 27). As we
enter an era of expanded use of culture-independent enteric diag-
nosis, clinical context will be critical to patient management, and
it is important that test-ordering algorithms be designed to min-
imize the risk of finding results that are not relevant or misleading
(32).
Our study was unable to compare the performance character-
istics between LD-PCR and RM-PCR and between culture and
EIA because of the selective use of EIA for PCR-positive speci-
mens; only a subset of specimens were tested by all four methods.
Another limitation of our LD-PCR assay is the requirement for
overnight culture enrichment, which does not permit same-day
notification of the critical findings. However, RM-PCR not only
provided a rapid platform but also produced comparable sensitiv-
ity for a limited number of direct samples (Table 1). Although
both PCR assays effectively distinguished O157 from non-O157
STEC causes, recovery of the pathogen is still vital for STEC sero-
typing and genotyping and for disease control interventions.
In summary, our LD-PCR assay using enriched stool speci-
mens demonstrated greatly improved sensitivity for detection of
STEC, especially in pediatric settings where rapid sensitive diag-
nosis of STEC infections can prompt specific clinical actions and
avoidance of antibiotics (1, 2). Rapid diagnoses of gastrointestinal
infections caused by bacteria, viruses, and protozoa have become
available (e.g., RM-PCR assays with direct stool specimens). Mul-
tiple etiologies were found at higher frequencies (17%) among our
53 STEC-positive cases than were reported (3.6%) through Food-
Net sites (33). Diagnostic ability to differentiate O157 from non-
O157 STEC has significant clinical implications, as infections
caused by STEC O157 are more likely to be admitted to hospitals
for supportive care and have a very much higher risk of progress-
ing to HUS. For the present, we would consider any child with
diarrhea who is determined to be infected with STEC to be at risk
for HUS, with treatment as if infected with E. coli O157:H7 (34).
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